Pharmacogenetics of Cannabinoid Response
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00678730 |
Recruitment Status
:
Active, not recruiting
First Posted
: May 15, 2008
Last Update Posted
: June 23, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COMT Gene Polymorphism | Drug: delta 9 tetrahydrocannabinol | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 162 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | Pharmacogenetics of Cannabinoid Response |
Study Start Date : | July 2007 |
Estimated Primary Completion Date : | July 2018 |
Estimated Study Completion Date : | July 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
|
Drug: delta 9 tetrahydrocannabinol
0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Other Names:
|
Placebo Comparator: 2
small amount of ethanol, (quarter teaspoon), with no THC
|
Drug: delta 9 tetrahydrocannabinol
0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Other Names:
|
- Behavioral Measures [ Time Frame: Baseline, +15, +25, +60, +300 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18 and 55 years (extremes included) on the day of the first dosing.
Exclusion Criteria:
- Cannabis naïve individuals.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00678730
United States, Connecticut | |
VA Connecticut Healthcare System | |
West Haven, Connecticut, United States, 06516 |
Principal Investigator: | Deepak D'Souza, M.D. | Yale University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Deepak C. D'Souza, Principal Investigator, Yale University |
ClinicalTrials.gov Identifier: | NCT00678730 History of Changes |
Other Study ID Numbers: |
0706002754 |
First Posted: | May 15, 2008 Key Record Dates |
Last Update Posted: | June 23, 2017 |
Last Verified: | June 2017 |
Keywords provided by Deepak C. D'Souza, Yale University:
THC COMT gene polymorphism schizophrenia cannabis use |
Additional relevant MeSH terms:
Ethanol Dronabinol Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Hallucinogens Psychotropic Drugs Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |